Which has stronger earnings and valuation, BFRGW or OABIW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bullfrog AI $298.80K N/A N/A N/A N/A OmniAb $38.46M N/A N/A N/A N/A

Is BFRGW or OABIW more profitable?

Company Net Margins Return on Equity Return on Assets Bullfrog AI N/A N/A N/A OmniAb N/A N/A N/A

Do analysts rate OABIW or TMO?

Thermo Fisher Scientific has a consensus price target of $624.64, indicating a potential downside of 4.02%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Thermo Fisher Scientific is more favorable than OmniAb. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OmniAb 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Thermo Fisher Scientific 2 Sell rating(s) 5 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 2.73

Which has preferable earnings and valuation, OABIW or TMO?

Thermo Fisher Scientific has higher revenue and earnings than OmniAb. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OmniAb $38.46M N/A N/A N/A N/A Thermo Fisher Scientific $44.56B 5.40 $6.70B $18.59 35.01

Do analysts prefer OABIW or DHR?

Danaher has a consensus target price of $228.91, indicating a potential upside of 8.19%. Given Danaher's stronger consensus rating and higher possible upside, analysts clearly believe Danaher is more favorable than OmniAb. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OmniAb 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Danaher 0 Sell rating(s) 5 Hold rating(s) 18 Buy rating(s) 2 Strong Buy rating(s) 2.88

Which has preferable valuation & earnings, OABIW or DHR?

Danaher has higher revenue and earnings than OmniAb. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OmniAb $38.46M N/A N/A N/A N/A Danaher $24.57B 6.05 $3.61B $5.63 37.58

Is OABIW or DHR more profitable?

Danaher has a net margin of 15.95% compared to OmniAb's net margin of 0.00%. Danaher's return on equity of 11.04% beat OmniAb's return on equity. Company Net Margins Return on Equity Return on Assets OmniAb N/A N/A N/A Danaher 15.95% 11.04% 6.81%

Do analysts recommend OABIW or IQV?

IQVIA has a consensus target price of $248.00, suggesting a potential downside of 7.01%. Given IQVIA's stronger consensus rating and higher possible upside, analysts clearly believe IQVIA is more favorable than OmniAb. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OmniAb 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 IQVIA 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.88

Which has stronger earnings and valuation, OABIW or IQV?

IQVIA has higher revenue and earnings than OmniAb. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OmniAb $38.46M N/A N/A N/A N/A IQVIA $16.31B 2.69 $1.36B $8.06 33.09

Is OABIW or IQV more profitable?

IQVIA has a net margin of 8.10% compared to OmniAb's net margin of 0.00%. IQVIA's return on equity of 30.25% beat OmniAb's return on equity. Company Net Margins Return on Equity Return on Assets OmniAb N/A N/A N/A IQVIA 8.10% 30.25% 6.54%

Do analysts prefer OABIW or A?

Agilent Technologies has a consensus price target of $170.33, indicating a potential upside of 9.02%. Given Agilent Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Agilent Technologies is more favorable than OmniAb. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OmniAb 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Agilent Technologies 0 Sell rating(s) 5 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has better earnings & valuation, OABIW or A?

Agilent Technologies has higher revenue and earnings than OmniAb. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OmniAb $38.46M N/A N/A N/A N/A Agilent Technologies $6.95B 6.34 $1.30B $5.08 30.76

OmniAb (OABIW) Competitors

$0.28 -0.09 (-23.27%)

As of 09/18/2026 01:53 PM Eastern

Compare

OABIW vs. BFRGW, TMO, DHR, IQV, and A

Should you buy OmniAb stock or one of its competitors? OmniAb's main competitors and comparable companies include Bullfrog AI (BFRGW), Thermo Fisher Scientific (TMO), Danaher (DHR), IQVIA (IQV), and Agilent Technologies (A). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does OmniAb compare to Bullfrog AI?

Bullfrog AI (NASDAQ:BFRGW) and OmniAb (NASDAQ:OABIW) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	N/A	N/A
OmniAb	N/A	N/A	N/A

In the previous week, Bullfrog AI's average media sentiment score of 0.00 equaled OmniAb'saverage media sentiment score.

Company	Overall Sentiment
Bullfrog AI	Neutral
OmniAb	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$298.80K	N/A	N/A	N/A	N/A
OmniAb	$38.46M	N/A	N/A	N/A	N/A

Summary

OmniAb beats Bullfrog AI on 1 of the 1 factors compared between the two stocks.

How does OmniAb compare to Thermo Fisher Scientific?

OmniAb (NASDAQ:OABIW) and Thermo Fisher Scientific (NYSE:TMO) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

In the previous week, Thermo Fisher Scientific had 23 more articles in the media than OmniAb. MarketBeat recorded 23 mentions for Thermo Fisher Scientific and 0 mentions for OmniAb. Thermo Fisher Scientific's average media sentiment score of 1.10 beat OmniAb's score of 0.00 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company	Overall Sentiment
OmniAb	Neutral
Thermo Fisher Scientific	Positive

89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 0.3% of Thermo Fisher Scientific shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Thermo Fisher Scientific has higher revenue and earnings than OmniAb.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$38.46M	N/A	N/A	N/A	N/A
Thermo Fisher Scientific	$44.56B	5.40	$6.70B	$18.59	35.01

Thermo Fisher Scientific has a net margin of 15.04% compared to OmniAb's net margin of 0.00%. Thermo Fisher Scientific's return on equity of 17.09% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	N/A	N/A	N/A
Thermo Fisher Scientific	15.04%	17.09%	8.12%

Thermo Fisher Scientific has a consensus price target of $624.64, indicating a potential downside of 4.02%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Thermo Fisher Scientific is more favorable than OmniAb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Thermo Fisher Scientific	2 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.73

Summary

Thermo Fisher Scientific beats OmniAb on 12 of the 12 factors compared between the two stocks.

How does OmniAb compare to Danaher?

OmniAb (NASDAQ:OABIW) and Danaher (NYSE:DHR) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Danaher has a consensus target price of $228.91, indicating a potential upside of 8.19%. Given Danaher's stronger consensus rating and higher possible upside, analysts clearly believe Danaher is more favorable than OmniAb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Danaher	0 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.88

79.1% of Danaher shares are held by institutional investors. 10.8% of Danaher shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Danaher has a net margin of 15.95% compared to OmniAb's net margin of 0.00%. Danaher's return on equity of 11.04% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	N/A	N/A	N/A
Danaher	15.95%	11.04%	6.81%

In the previous week, Danaher had 12 more articles in the media than OmniAb. MarketBeat recorded 12 mentions for Danaher and 0 mentions for OmniAb. Danaher's average media sentiment score of 0.89 beat OmniAb's score of 0.00 indicating that Danaher is being referred to more favorably in the news media.

Company	Overall Sentiment
OmniAb	Neutral
Danaher	Positive

Danaher has higher revenue and earnings than OmniAb.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$38.46M	N/A	N/A	N/A	N/A
Danaher	$24.57B	6.05	$3.61B	$5.63	37.58

Summary

Danaher beats OmniAb on 12 of the 12 factors compared between the two stocks.

How does OmniAb compare to IQVIA?

OmniAb (NASDAQ:OABIW) and IQVIA (NYSE:IQV) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

89.6% of IQVIA shares are held by institutional investors. 1.7% of IQVIA shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

IQVIA has higher revenue and earnings than OmniAb.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$38.46M	N/A	N/A	N/A	N/A
IQVIA	$16.31B	2.69	$1.36B	$8.06	33.09

IQVIA has a consensus target price of $248.00, suggesting a potential downside of 7.01%. Given IQVIA's stronger consensus rating and higher possible upside, analysts clearly believe IQVIA is more favorable than OmniAb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

IQVIA has a net margin of 8.10% compared to OmniAb's net margin of 0.00%. IQVIA's return on equity of 30.25% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	N/A	N/A	N/A
IQVIA	8.10%	30.25%	6.54%

In the previous week, IQVIA had 10 more articles in the media than OmniAb. MarketBeat recorded 10 mentions for IQVIA and 0 mentions for OmniAb. IQVIA's average media sentiment score of 0.66 beat OmniAb's score of 0.00 indicating that IQVIA is being referred to more favorably in the news media.

Company	Overall Sentiment
OmniAb	Neutral
IQVIA	Positive

Summary

IQVIA beats OmniAb on 12 of the 12 factors compared between the two stocks.

How does OmniAb compare to Agilent Technologies?

OmniAb (NASDAQ:OABIW) and Agilent Technologies (NYSE:A) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

In the previous week, Agilent Technologies had 9 more articles in the media than OmniAb. MarketBeat recorded 9 mentions for Agilent Technologies and 0 mentions for OmniAb. Agilent Technologies' average media sentiment score of 1.24 beat OmniAb's score of 0.00 indicating that Agilent Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
OmniAb	Neutral
Agilent Technologies	Positive

Agilent Technologies has a net margin of 19.53% compared to OmniAb's net margin of 0.00%. Agilent Technologies' return on equity of 24.45% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	N/A	N/A	N/A
Agilent Technologies	19.53%	24.45%	13.09%

Agilent Technologies has a consensus price target of $170.33, indicating a potential upside of 9.02%. Given Agilent Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Agilent Technologies is more favorable than OmniAb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Agilent Technologies	0 Sell rating(s)	5 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.80

Agilent Technologies has higher revenue and earnings than OmniAb.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$38.46M	N/A	N/A	N/A	N/A
Agilent Technologies	$6.95B	6.34	$1.30B	$5.08	30.76

Summary

Agilent Technologies beats OmniAb on 10 of the 10 factors compared between the two stocks.

Get OmniAb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OABIW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OABIW vs. The Competition

Export

Metric	OmniAb	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	N/A	$10.40B	$7.24B	$13.19B
Dividend Yield	N/A	1.46%	2.57%	12.81%
P/E Ratio	N/A	70.70	274.93	25.38
Price / Sales	N/A	108.53	646.01	89.45
Price / Cash	N/A	27.47	76.25	51.42
Price / Book	N/A	5.70	10.46	6.33
Net Income	N/A	$56.67B	$3.49B	$358.33M
7 Day Performance	2.55%	4.59%	0.59%	1.12%
1 Month Performance	-0.88%	0.07%	-1.74%	-2.39%
1 Year Performance	N/A	27.93%	18.13%	5.35%

OmniAb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OABIW OmniAb	N/A	$0.28 -23.3%	N/A	+98.6%	$0.00	$38.46M	N/A	106	Short Interest Decrease
BFRGW Bullfrog AI	N/A	$0.09 -2.9%	N/A	N/A	$0.00	$298.80K	N/A	2
TMO Thermo Fisher Scientific	3.7769 of 5 stars	$603.81 -0.3%	$624.64 +3.5%	+35.6%	$223.26B	$44.56B	32.48	125,000	Positive News Ex-Dividend
DHR Danaher	4.1293 of 5 stars	$200.58 -2.1%	$228.91 +14.1%	+9.5%	$141.01B	$24.57B	35.63	60,000	Dividend Announcement Analyst Upgrade
IQV IQVIA	3.6468 of 5 stars	$257.54 +0.2%	$243.63 -5.4%	+42.4%	$42.39B	$16.31B	31.95	93,000	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OABIW) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OmniAb (OABIW) Competitors